Syndrome Differentiation and Treatment of COVID-19 by Academician Tong Xiaolin:Origin, Innovation, and Development of "Cold-Dampness Plague" Theory

YANG Yingying; LI Qingwei; BAO Tingting; SONG Bin; LEI Ye; GAO Zezheng; SHEN Shiwei; WANG Qiang; ZHAO Linhua; TONG Xiaolin

doi:10.3969/j.issn.1673-7202.2022.06.014

Suggestions

您当前的位置：

首页 >

文章列表页 >

Syndrome Differentiation and Treatment of COVID-19 by Academician Tong Xiaolin:Origin, Innovation, and Development of "Cold-Dampness Plague" Theory

Previous: Application of Modified Bupleurum plus Os Draconis and Oyster Shell Decoction in the Treatment of Palpitation Based on the Syndrome Differentiation Model of Generation⁃Restraint⁃Transformation of Five Zang Organs

Next: Professor Zhang Shengsheng's TCM Clinical Experience in Syndrome Differentiation and Treatment of Ulcerative Colitis

Syndrome Differentiation and Treatment of COVID-19 by Academician Tong Xiaolin:Origin, Innovation, and Development of "Cold-Dampness Plague" Theory
1.Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
2.Beijing University of Chinese Medicine, Beijing 100029, China
3.The Third Affiliated Hospital of Zunyi Medical University, Zunyi 563002, China
4.The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000, China
5.Human Phenome Institute, Fudan University, Shanghai 200433, China
6.Northeast International Hospital, Shenyang 110623, China
DOI：10.3969/j.issn.1673-7202.2022.06.014

扫描看全文

YANG Yingying, LI Qingwei, BAO Tingting, et al. Syndrome Differentiation and Treatment of COVID-19 by Academician Tong Xiaolin:Origin, Innovation, and Development of "Cold-Dampness Plague" Theory[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1673-7202.2022.06.014
DOI：

YANG Yingying, LI Qingwei, BAO Tingting, et al. Syndrome Differentiation and Treatment of COVID-19 by Academician Tong Xiaolin:Origin, Innovation, and Development of "Cold-Dampness Plague" Theory[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1673-7202.2022.06.014 DOI：

摘要

2019年末至2020年初，武汉地区暴发新型冠状病毒肺炎，仝小林院士在一线抗疫60余日。在此期间，他提出和制定了诸多学术观点和实践方案：1)创“三维定性”之法，并依此而将武汉新冠疫情定性为“寒湿疫”。2)针对“寒湿疫”早期，制宣肺化湿之法，并依此开具寒湿疫方，对疫情进行早期截断。3)创“武昌模式”高效有序推行寒湿疫方，将防控重心下沉前移至社区。4)针对“寒湿疫”重症期，发现“瘀热入营”是转重之关键病机，并制定了系列治法。5)针对“寒湿疫”恢复期，提出从“虚、毒、瘀”去辨治的临床策略，并依此制定了恢复期通治方。6)从“分期—分证”的角度，结合“治未病”理论，将“寒湿疫”分为“四期十六证”，建立了相对完善的“寒湿疫”辨治体系。

Abstract

From the end of 2019 to the beginning of 2020, Wuhan experienced the epidemic of COVID-19, and Academician Tong Xiaolin fought against the epidemic for more than 60 days. During this period, he put forward many academic viewpoints and practical plans, which are listed below.1) He identified COVID-19 as "cold-dampness plague" based on the "three-dimensional qualitative" method.2) For the early-stage patients, he formulated the formulas targeting the "cold-dampness plague" (Hanshiyi Formulas for short) by ventilating lung and resolving dampness to cut off the epidemic at an early stage.3) He created the "Wuchang Pattern" to efficiently carry out Hanshiyi Formulas, and shifted the focus of prevention and control to the communities.4) For the patients at the critical stage, he discovered that "stagnant heat entering nutrient-blood" was the key pathogenesis of the exacerbation, and formulated a series of treatment methods.5) For the patients at the convalescent stage, he proposed a clinical strategy of syndrome differentiation and treatment from "deficiency, toxin, and blood stasis", and formulated a general formula for the recovery period accordingly.6) From the perspective of "staging-syndrome differentiation", he divided the "cold-dampness plague" into four stages and 16 syndromes based on the theory of "treating disease before its onset", and established a complete system of differentiation and treatment of "cold-dampness plague".

关键词

新型冠状病毒肺炎中医药寒湿疫三维定性寒湿疫方辨治体系仝小林

Keywords

COVID-19Traditional Chinese medicineCold-dampness plagueThree-dimensional qualitative methodHanshiyi FormulasSyndrome differentiation and treatment systemTong Xiaolin

references

范逸品, 刘鲲鹏, 王乐, 等.寒疫论治[J].中国中医基础医学杂志, 2012, 18(4): 356,359.

南东求, 张学梅.圣散子方考[J].黄冈职业技术学院学报, 2012, 14(3): 84-86.

张仲景, 王叔和, 钱超尘.伤寒论[M].北京: 人民卫生出版社, 2012:18-30.

赵绍琴.谈谈我对“在卫汗之”的认识[J].中医杂志, 1981, 22(8): 57-59.

仝小林, 李修洋, 赵林华, 等.从“寒湿疫”角度探讨新型冠状病毒肺炎的中医药防治策略[J].中医杂志, 2020, 61(6): 465-470,553.

Biryukov J, Boydston JA, Dunning RA, et al. Increasing Temperature and Relative Humidity Accelerates Inactivation of SARS-CoV-2 on Surfaces[J/OL].mSphere, 2020, 5(4): e00441-20.[2020-0701].https://journals.asm.org/doi/10.1128/mSphere.00441-20https://journals.asm.org/doi/10.1128/mSphere.00441-20.

央视新闻.中国工程院院士：新冠病毒喜冷怕热，前一年10月到次年4月高发[EB/OL].(2020-02-09)[2020-10-2].https://new.qq.com/omn/20200209/20200209A0OL6R00?ADTAG=LenovoPChttps://new.qq.com/omn/20200209/20200209A0OL6R00?ADTAG=LenovoPC.

央视新闻.新冠病毒可由物传人青岛首次找到证据链[EB/OL].(2020-10-20)[2020-10-25].https://tv.cctv.com/2020/10/20/ARTIiERXERwUnp5CjXUm31Bu201020.shtmlhttps://tv.cctv.com/2020/10/20/ARTIiERXERwUnp5CjXUm31Bu201020.shtml.

仝小林.新冠肺炎中医诊疗与研究[M].北京: 科学出版社, 2020:26-60.

姜德友, 吴佳姝.湿温病源流考[J].中国中医急症, 2017, 26(8): 1397-1400,1408.

宋斌, 雷烨, 赵林华, 等.“通治方”在防治新型冠状病毒肺炎中的运用及其创新发展[J].中国新药杂志, 2020, 29(16): 1807-1812.

仝小林, 何莉莎, 赵林华.论“态靶因果”中医临床辨治方略[J].中医杂志, 2015, 56(17): 1441-1444.

李晓东, 刘保延, 王辉, 等.从治未病谈“武昌模式”在突发性急性传染病防控中的意义[J].南京中医药大学学报, 2021, 37(1): 1-5.

武汉市新冠肺炎防控指挥部医疗救治组.关于在新型冠状病毒感染的肺炎中医药治疗中推荐使用中药协定方的通知[EB/OL].(2020-02-02)[2020-11-09].https://www.sohu.com/a/370642362_100199400https://www.sohu.com/a/370642362_100199400.

人民日报.仝小林：中医要冲在抗疫一线[EB/OL].(2020-04-28)[2020-11-09].https://mp.weixin.qq.com/s/C5a-KW4G9UI-B5rqWDF6Csghttps://mp.weixin.qq.com/s/C5a-KW4G9UI-B5rqWDF6Csg.

Tian J, Yan S, Wang H, et al. Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study[J]. Pharmacol Res, 2020, 161:105127.

国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第八版)[EB/OL].(2020-8-18)[2020-10-2]. http://www.nhc.gov.cn/xcs/zhengcwj/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a/files/a449a3e2e2c94d9a856d5faea2ff0f94.pdfhttp://www.nhc.gov.cn/xcs/zhengcwj/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a/files/a449a3e2e2c94d9a856d5faea2ff0f94.pdf.

Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19[J]. Lancet, 2020, 395(10234):1417-1418.

Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19[J]. N Engl J Med, 2020, 383(2):120-128.

Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study[J]. Lancet Haematol, 2020, 7(8):575-575,582.

He S, Tian J, Li X, et al. Positive RT-PCR Test Results in 420 Patients Recovered From COVID-19 in Wuhan: An Observational Study[J]. Front Pharmacol, 2020, 11:549117.

国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒肺炎恢复期中医康复指导建议(试行)[EB/OL].(2020-02-22)[2020-11-09]. http://www.xinhuanet.com/health/2020-02/24/c_1125616980.htmhttp://www.xinhuanet.com/health/2020-02/24/c_1125616980.htm.

Xiao M, Tian J, Zhou Y, et al. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial[J]. Pharmacol Res, 2020, 161:105126.

Chen G, Su W, Yang J, et al. Chinese herbal medicine reduces mortality in patients with severe and critical Coronavirus disease 2019: a retrospective cohort study[J]. Front Med, 2020, 14(6):752-759.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Treating DPN Based on Collateral Diseases by Professor TONG Xiaolin

A case study of the treatment of a hyperthyroidism patient allergic to methimazole by Academician Tong Xiaolin

A case report of the treatment of diabetic kidney disease at the stage of macroalbuminuria by Academician Tong Xiaolin

A case report about Professor Tong Xiaolin’s diagnosis and treatment of adult type 1 brittle diabetes with multiple system complications by the state-target-cause-result differentiation theory

Experience on Discussion and Analysis on Application of Cancer Toxicology Theory

Related Author

No data

Related Institution

Guang’anmen Hospital of China Academy of Chinese Medical Sciences

Gansu University of Chinese Medicine

Guang’ anmen Hospital, China Academy of Chinese Medical Sciences

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

The Third Clinical Medical College, Nanjing University of Chinese Medicine

⁰